Thor Medical ASA: Primary insider transaction and disclosure of large shareholding
18.6.2025 23:41:14 CEST | Thor Medical ASA | Major shareholding notifications
Oslo, Norway, 18 June 2025: Reference is made to the stock exchangeannouncements by Thor Medical ASA (the "Company") on 18 June 2025 regardingthecompletion of a private placement of new shares to be issued by the Company(the"Private Placement") and a retail offering through PrimaryBid (the "PrimaryBidOffering").
Scatec Innovation AS has agreed to lend existing and unencumbered shares intheCompany, already being traded on Euronext Oslo Børs, to Arctic Securities ASandDNB Carnegie, a part of DNB Bank ASA (the "Managers") for the PrivatePlacementand the PrimaryBid Offering. Borrowed shares will be used for settlementtowardsinvestors having been allocated shares in the Private Placement and thePrimaryBid Offering and redelivered to Scatec Innovation AS upon registrationofthe share capital increase pertaining to the Private Placement and thePrimaryBid Offering.
Prior to the completion of the Private Placement, Scatec Innovation AS held78,419,309 shares in the Company, representing approx. 24.94% of the issuedshare capital and votes. Scatec Innovation AS has lent a total of 31,577,399existing shares which will be delivered to the investors in the PrivatePlacement and the PrimaryBid Offering other than Scatec Innovation AS. Duringthe term of the loan, and prior to the redelivery, Scatec Innovation AS'shareholding in the Company will be reduced to 46,841,910, equivalent toapprox.14.90% of the issued share capital and votes. Consequently, Scatec InnovationAShas fallen below the 20 and 15% thresholds pursuant to section 4-2 (1) and (3)of the Norwegian Securities Trading Act.
In addition, Scatec Innovation AS has controlling interest in Scatec Invest IVAS, which holds 1,281,338 shares in the Company. Scatec Innovation AS'aggregated shareholding is thus 48,123,248 after the share lending, equivalentto approx. 15,31% of the issued share capital and votes in the Company.
The board of directors of the Company has resolved to issue 30,000,000 offershares in the Private Placement and 4,577,399 offer shares in the PrimaryBidOffering pursuant to the authorisation granted by the Company's annual generalmeeting held on 24 April 2025, that will be subscribed by the Managers, and,once issued, delivered to Scatec Innovation AS as redelivery of sharesborrowedin relation to settlement of the Private Placement and the PrimaryBidOffering,as well as delivery of 3,000,000 shares allocated to Scatec Innovation AS inthePrivate Placement.
Scatec Innovation AS is a close associate of chairman John Andersen. Primaryinsider notification pursuant to the market abuse regulation article 19 isattached.
This announcement is published in accordance with section 4-2 of the NorwegianSecurities Trading Act and is subject to disclosure requirements pursuant totheEU Market Abuse Regulation article 19 (3) and the Norwegian Securities TradingAct section 5-12.
Contacts
Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alphaparticleemitters, from naturally occurring thorium. Its proprietary production processrequires no irradiation or use of nuclear reactors, and provides reliable,environmentally friendly, cost-efficient supply of alpha-emitters for theradiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norwayandlisted on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.no - http://www.thormedical.no
ATTACHMENTS
Download announcement as PDF.pdf -https://kommunikasjon.ntb.no/ir-files/17848634/18570366/6227/Download%20announcement%20as%20PDF.pdf
20250618 - Primary insider notifications Scatec Innovation AS.pdf -https://kommunikasjon.ntb.no/ir-files/17848634/18570366/6226/20250618%20-%20Primary%20insider%20notifications%20Scatec%20Innovation%20AS.pdf
https://newsweb.oslobors.no/message/649548
